Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Academic conferenceADC / XDC

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting

Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting
Academic conferenceClinical trial results

Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting

BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC
BeOne MedicinesHER2

BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC

MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting
ADC / XDCCancer

MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting

Show More